Zydus Cadila has received the final approval from the USFDA to market Acyclovir Ointment USP (US RLD- Zovirax@), 5%. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
Acyclovir is an antiviral drug which stops the growth of certain viruses. This medication is used to treat the first outbreak of genital herpes infection. It is also used to treat non-life threatening herpes infections of the skin and around the mouth (cold sores) in people with a weakened immune system.
The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare Ltd is currently trading at Rs339.05 down by Rs0.2 or 0.06% from its previous closing of Rs339.25 on the BSE.
The scrip opened at Rs340.10 and has touched a high and low of Rs344 and Rs338.75 respectively. So far 6,93,035 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs34,730.47cr.